RAVENSBURG, FEDERAL REPUBLIC OF GERMANY, RANKWEIL, Austria AND SKOKIE, USA – Media OutReach With the growing development of new drugs and pharmaceuticals for new treatments, more and more pharmaceutical and biotech companies are looking for clinical manufacturing partners to help meet demand. for complex filling and finishing solutions. While the initial stages of drug development are complex and challenging, Vetter, a world-leading Contract Development and Manufacturing Organization (CDMO) is committed to solving the problem. this by providing comprehensive specialist manufacturing services for clinical trials and supporting the commercialization of their customers’ products. Proof of this commitment is the success of the Skokie facility which has contributed to bringing 5 new products for customers to market since the facility started fully operational in 2011. It is expected, 4 products. Another new product from Vetter’s US drug development facility Skokie is expected to launch in the coming months.
Since its opening and opening, the facility has seen over 240 successfully completed customer audits. Currently, Vetter Development Services is running more than 80 projects in clinical development phases I and II. Over the years, the Skokie drug development facility in the US has made more than 30 transfers from initial clinical projects to Germany for further development in the late stages.
“Our clinical manufacturing facilities are an essential part of Vetter’s commercial business,” said Dr. Claus Feussner, Senior Vice President of Development Services at Vetter. And the Skokie facility has demonstrated an impressive track record of success since its opening 12 years ago. In the last year alone, we have acquired more than 10 new customers and their promising customers.”
Carsten Press, Senior Vice President of Principal Account Management, Supply Chain Management and Marketing at Vetter added: “Overall, our continued investments in clinical drug development capabilities is proof of Vetter’s consistent strategic approach to keeping up with the market and our focus on the critical drug development needs of our customers.”
In addition to Vetter America’s Development Services, Vetter’s latest clinical manufacturing facility in Rankweil (Austria) has also enhanced the company’s capabilities in the critical area of process development as well as clinical manufacturing. Phase I and II injections for clients.
Acquired by Vetter in 2020, the facility received its production license in late 2021 and successfully completed filling its first customers early last year. Vetter Development Services Austria serves as the European partner of Vetter Development Services USA, helping to expand Vetter’s international presence and enhance overall capabilities.
Since being taken over by Vetter, the clinical production facility at Rankweil has proven highly productive, with 14 projects already successful and many more in the pipeline and promising to deliver results soon. fruit.
Hashtag: #Vetter
The publisher is solely responsible for the content of this notice.
Information regarding Vetter
Headquartered in Ravensburg (Germany), Vetter is the world’s leading family-owned contract development and manufacturing organization (CDMO) with manufacturing facilities in Germany, Austria and the US. Currently employing more than 5,700 people worldwide, the company has a long history of supporting biotech and pharmaceutical clients both large and small. Vetter’s services range from supporting early stage development including clinical production, to providing commercial and wide range of packaging solutions for vials, syringes, and more.
As a leading solutions provider, Vetter appreciates its responsibility to support the needs of its customers by developing devices that contribute to enhanced patient safety, convenience and enhanced reliability. follow. Social responsibility is also emphasized by Vetter, including environmental protection and sustainability.
More regarding Vetter can be found at www.vetter-pharma.com.
.
